Rusfertide
Jul 10, 2025
Polycythemia Vera: Growing Competition and the Changing Treatment Landscape in 2025
JAKAFI’s demand continues to grow in Polycythemia Vera The therapeutic paradigm for polycythemia vera treatment has evolved notably in recent years. Historically managed with generics like aspirin, hydroxyurea, phlebotomy, and interferons, the landscape shifted dramatically with the FDA approval of JAKAFI (rux...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
